{"id":"W2791796775","doi":"10.1016/s0022-5347(18)33424-4","title":"1199: Canadian Urologic Oncology Group (CUOG) Phase II Study Using Docetaxel/Prednisone in the Second Line Setting for Metastatic Androgen Independent Prostate Cancer in Patients Progressing after First Line Mitoxantrone/Prednisone","year":2006,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Mitoxantrone; Medicine; Prednisone; Docetaxel; Prostate cancer; Oncology; Internal medicine; Cancer; Chemotherapy","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001130107,0.0009077612,0.001432394,0.0003862298,0.0009130068,0.0008805757,0.0006688869,0.0009990152,0.003762274],"category_scores_gemma":[0.0008750553,0.0004885482,0.0009790019,0.0007476057,0.0006468293,0.0002931743,0.0002502889,0.002209776,0.0004798984],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003913519,"about_ca_system_score_gemma":0.008113611,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.1159282,"about_ca_topic_score_gemma":0.3974643,"domain_scores_codex":[0.9994693,0.0002142404,0.00002098569,0.00005690471,0.00009909311,0.0001394855],"domain_scores_gemma":[0.9992691,0.0000524836,0.00006838927,0.00002317818,0.00006053622,0.0005264334],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7072322,0.04110175,0.07501438,0.001058051,0.004616626,0.0006262537,0.0004443031,0.001561114,0.02184609,0.0003698798,0.02581344,0.1203159],"study_design_scores_gemma":[0.5483021,0.2036844,0.226628,0.00009511251,0.002604495,0.0003768599,0.0001107174,0.0008316588,0.002473819,0.0001288692,0.0146944,0.00006948964],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.986214,0.003272988,0.0001371267,0.001138897,0.0002796254,0.002183327,0.003537913,0.00005104167,0.003185171],"genre_scores_gemma":[0.9859349,0.002135959,0.0008642804,0.001654343,0.0001963066,0.0007360451,0.004696197,0.00002176142,0.003760191],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1159282,"threshold_uncertainty_score":0.2305068,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02917997984628917,"score_gpt":0.3510711161239282,"score_spread":0.321891136277639,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}